alexa Statins Added to Chronic Hepatitis C Treatment: Is it B
ISSN: 2475-3181

Journal of Hepatology and Gastrointestinal disorders
Open Access

Like us on:
OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Research Article

Statins Added to Chronic Hepatitis C Treatment: Is it Beneficial?

Mohamed AA1, El-Halawany F2, El-Nabarawy N3, Zayed N4, Omar H4*, El-Kasas M5 and El-Gohary K6

1Department of Biochemistry, National Hepatology and Tropical Medicine Institute, Egypt

2Faculty of Science for Girls, Department of Statistics, King Abdulaziz University, Jeddah and Lecturer, Statistics Expert, Cairo University, Egypt

3Faculty of Medicine, National Egyptian Center of Environmental and Toxicology Research (NECETR), Cairo University, Egypt

4Faculty of Medicine, Department of Endemic Medicine and Hepatology, Cairo University, Egypt

5Faculty of Medicine, Department of Internal Medicine, Helwan University, Egypt

6Departments of Biochemistry, El Sahel Teaching Hospital, Egypt

*Corresponding Author:
Omar H
MD, Lecturer in Endemic Medicine and Hepatology
Department, Faculty of Medicine, Cairo University, Egypt
Tel: 01007032146
Email: [email protected]

Received date: February 12, 2016; Accepted date: February 24, 2016; Published date: March 02, 2016

Citation: Mohamed AA, El-Halawany F, El-Nabarawy N, Zayed N, Omar H, et al. (2016) Statins Added to Chronic Hepatitis C Treatment: Is it Beneficial?. J Hepatol Gastroint Dis 2:117. doi:10.4172/2475-3181.1000117

Copyright: © 2016 Mohamed AA, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

 

Abstract

Objectives: Chronic hepatitis C (CHC) is a major health problem in Egypt with about 9.8% of Egyptian population having an active hepatitis C infection. Almost Every step in the Hepatitis C virus (HCV) life cycle is closely related to lipid metabolism. HCV circulate in the body in lipid-rich particle, attach to hepatocytes via lipoprotein receptors. Recent attention focused on HMG CoA Reductase inhibitors (statins) and their potential therapeutic role in hepatitis C.

Methods: This retrospective closed cohort study included 60 naïve CHC patients. The HCV statins group patients (n = 26) received the combination of Standard of care (Interferon alfa and repavirin) and fluvastatin 80 mg daily; HCV non statins group (n = 43) treated with the SOC treatment only. Both groups receive their treatment over a duration of 48 weeks.

Results: On-treatment viral responses as well as the SVR were significantly better in HCV statins group in comparison to HCV non statins group; rapid virological response (RVR), early virological response (EVR) and sustained virological response (SVR) were (13.3%, 73.3% and 68.3%) in HCV statins group vs. (0%, 58.8% and 52.9%) HCV non statins group with p value 0.00, 0.003 and 0.003 respectively. Multivariate logistic regression model identified statins use as a significant predictor of an SVR.

Conclusion: A combination of fluvastatin and SOC significantly improved the SVR in naïve CHC Egyptian patients. Further powered randomized control trails are needed to elucidate statins role in HCV treatment.

Keywords

Share This Page

Additional Info

Loading
Loading Please wait..
 
Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

 
© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords